US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB
BlockBeats News, July 28th, According to a report by businessinsider, Clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) today announced plans to strategically expand into the cryptocurrency and blockchain space.
The company plans to establish a subsidiary named "American BNB Strategy" to lead its digital asset investment and management plan. Through this platform, Liminatus plans to gradually raise and deploy up to $500 million in funds, with the goal of strategically long-term investing in BNB.
Liminatus emphasized that while the company remains fully committed to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is seen as a necessary step to support long-term growth and enhance shareholder value.
Liminatus is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer patients. The company is advancing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.
You may also like
Gainers
Latest Crypto News
Key Transaction Data: US 10-Year Treasury Yield Rises to 4.086%
Mainstream Perp DEX Overview: Hyperliquid Surpasses $10 Billion in Trading Volume Again, Platform Volumes Rebound Collectively
The European Stablecoin Alliance Appoints Former Coinbase Executive as Chief Executive Officer
Ethereum ICO Whale with 254,900 Tokens Nearing Liquidation, Deposited 23,000 ETH to CEX in the Past Week
The Central Bank of Russia has confirmed that it may relax cryptocurrency regulation rules.
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Services:support@weex.com